Scientific Presentations & Conferences
EASL 2023
- CAM-E ALG-000184, Treatment for up to 24 weeks with the capsid assembly modulator ALG-000184 results in dose related reductions in HBsAg in subjects with HBeAg positive chronic hepatitis B
- siRNA ALG-125755, Safety, pharmacokinetics, and antiviral activity of single ascending doses of ALG-125755, a GalNAc-conjugated small interfering RNA, in subjects with chronic hepatitis B
- siRNA ALG-125755, Pharmacodynamic durability of ALG-125755, a GalNAc-conjugated siRNA, correlated with total and RNA induced complex (RISC) bound siRNA in mouse liver
- Small molecule PD-L1 inhibitor ALG-093702, Preclinical pharmacokinetic, pharmacodynamic and efficacy relationships of ALG-093702, a liver targeted PD-L1 small molecule inhibitor, in different in vivo models
- siRNA PD-L1 inhibitor, A potent human PD-L1 siRNA leads to significant reduction of AAV-HBV infected hepatocytes via immune activation in human PD-1/PD-L1 double knock in mice
- Hepatitis B virus model system, An in vivo duck hepatitis B virus model recapitulates key aspects of nucleic acid polymer treatment outcomes in chronic hepatitis B patients
- Hepatocellular carcinoma, Selective inhibition of human β-catenin DNA transactivation activity using splice switching oligonucleotides for an improved therapeutic window in treating hepatocellular carcinoma
APASL 2023
Posters
- Safety, Tolerability and Pharmacokinetics (PK) of Single Ascending Doses of ALG-125755, a GalNAc-Conjugated Small Interfering RNA (siRNA), in Healthy Volunteers (HV)
- ALG-000184, an Orally Administered Capsid Assembly Modulator (CAM) Reduces HBsAg in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)
- Discovery of a Liver-Targeted PD-L1 Small Molecule Inhibitor for the Treatment of Chronic Hepatitis B and Liver Cancer
- Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta (THR-β) Agonist for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia
- Preclinical Antiviral, Pharmacological and Toxicological Characteristics of ALG-000184, a Prodrug of the Novel HBV Capsid Assembly Modulator ALG‑001075
Oral Presentations
- The Capsid Assembly Modulator ALG-000184 Dosed for 28 Days Was Well Tolerated and Rapidly Reduced Viral Markers in Subjects with Chronic Hepatitis B, Including HBsAg in a Subset of HBeAg Positive Subjects with Elevated Baseline ALT
- Preclinical Profile of ALG-125755, a GalNAc-siRNA Targeting HBV
- ALG-000184, a Capsid Assembly Modulator, Demonstrates Superior Antiviral Activity in Combination with Entecavir Compared to Entecavir in HBeAg Positive Subjects with Chronic Hepatitis B infection
ACT 2022
- The Prodrug of a Novel Capsid Assembly Modulator (CAM), ALG-000184, Demonstrates a Favorable Nonclinical Toxicokinetic and Toxicology Profile for the Treatment of Chronic Hepatitis B (CHB)
- Lack of Translation of Favorable Nonclinical Toxicology Profile of Antisense Oligonucleotide (ASO) ALG-020572 to Chronic Hepatitis B (CHB) Patients
- Prediction of In Vivo Toxicity and Clinical Effects Using Antisense Oligonucleotides in an In Vitro Model Utilizing 3D Insight Human Liver Microtissues
AASLD 2022
- Discovery of Liver-targeted Oral PD-L1 Small Molecule Inhibitors for the Treatment of Chronic Hepatitis B and Liver Cancers
- Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with HBeAg Positive Chronic Hepatitis B (CHB)
- Safety and Tolerability of Multiple Doses of ALG-020572, a GalNAc-conjugated Antisense Oligonucleotide, in Chronic Hepatitis B Subjects
- SAFETY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF MULTIPLE ASCENDING ORAL DOSES OF ALG-055009, A THYROID HORMONE RECEPTOR BETA AGONIST, IN HYPERLIPIDAEMIC SUBJECTS
- Nonclinical efficacy, pharmacokinetic profile and pharmacokinetic/pharmacodynamic (PK/PD) correlation of ALG 125755, a GalNAc conjugated siRNA, for functional cure of chronic hepatitis B
- HAP Class I Capsid Assembly Modulators Clear Hepatitis B Virus-Infected Hepatocytes Through Core-dependent Hepatocyte Death and Subsequent Proliferation
- Non-HAP class I capsid assembly modulators have distinct profiles and a differentiated mechanism of action
- Suppression of PD-L1 expression by a novel liver-targeted siRNA leads to potential restoration of immune responses against HBV
EASL 2022
- Discovery of oral PDL1 small molecule inhibitors specifically designed for the treatment of chronic hepatitis B
- Safety and Pharmacokinetics (PK) of Single and Multiple Ascending Oral Doses of ALG-055009, a Thyroid Hormone Receptor Beta Agonist, for the Treatment of Non-Alcoholic Steatohepatitis (NASH), in Healthy Volunteers and Subjects with Hyperlipidaemia
- Safety, Pharmacokinetics, and Antiviral Activity of the Class II Capsid Assembly Modulator ALG-000184 in Subjects with Chronic Hepatitis B
- Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of ALG-020572, a GalNAc Conjugated Antisense Oligonucleotide, in Healthy Subjects
- Safety, Pharmacokinetics, and Antiviral Activity of the S-Antigen Transport Inhibiting Oligonucleotide Polymers (STOPSTM) Drug Candidate ALG-010133 in Subjects with Chronic Hepatitis B
- Incorporation of novel siRNA chemistries significantly improves the potency and durability of HBV siRNAs in the AAV-HBV mouse model
- The HBV siRNA, ALG-125755, demonstrates a favorable nonclinical profile and significant and durable hepatitis B surface antigen reductions in the AAV-HBV mouse efficacy model
APASL 2022
- Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Asian and non-Asian Subjects with Chronic Hepatitis B (CHB)
- Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG
000184 in Asian and non Asian Subjects with Chronic Hepatitis B (CHB) - Hepatitis B Surface Antigen (HBsAg) is Significantly Reduced by the HBV small interfering RNA (siRNA) ALG 125755 in HBV Infected Cells and the AAV HBV Mouse Model
ICAR 2022
AASLD 2021
Chronic Hepatitis B
S-antigen Transport-inhibiting Oligonucleotide Polymers(STOPSTM)
Capsid Assembly Modulator (CAM)
Antisense Oligonucleotide (ASO)
- Best-in-Class Antisense Oligonucleotides Against Hepatitis B Virus: Next Generation Bridged Nucleic Acid Chemistries Significantly Increase In Vivo Efficacy and Reduce Hepatotoxicity in Mice
- ALG-020572, a GalNAc-Conjugated Antisense Oligonucleotide, Demonstrates In Vivo Efficacy and Favorable Preclinical Profile for the Treatment of Chronic Hepatitis B
siRNA
Combinations
NASH
- Preclinical Pharmacokinetic Profiling of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of Nonalcoholic Steatohepatitis, and Prediction of its Human Pharmacokinetics
- Development of a Novel Seven-Day Dosing Mouse Efficacy Model to Evaluate Thyroid Hormone Receptor Agonists for the Treatment of NASH
Others
- Improved Liver Concentration and Activity of S-antigen Transport-Inhibiting Oligonucleotide Polymers
- ALG-005398 is a Potent Non-HAP Class I HBV Capsid Assembly Modulator that Strongly Reduces HBsAg Levels In Vivo
EASL 2021
- ALG-125755, a Small Interfering RNA (siRNA) Against Hepatitis B Virus (HBV) Effectively Inhibits Hepatitis B Surface Antigen (HBsAg) Secretion in HBV Cell Models and the AAV-HBV Mouse Model
- Combination drug interactions of hepatitis B virus ( HBV) small interfering RNA (siRNA) and antisense oligonucleotides (ASO) in vitro and in vivo
- Mechanism of Action of HBV S-antigen Transport-inhibiting Oligonucleotide Polymers (STOPSTM) Molecules
- Capsid Assembly Modulator ALG-000111 and its Prodrug ALG-000286 Display Excellent In Vitro and In Vivo Antiviral Activity
- Safety, Tolerability and Pharmacokinetics (PK) of Single and Multiple Doses of ALG-010133, an S-antigen Transport Inhibiting Oligonucleotide Polymer (STOPSTM), for the Treatment of Chronic Hepatitis B
CROI 2021
APASL 2021
- ALG-020572, a next generation hepatitis B virus (HBV) antisense oligonucleotide (ASO) with bridged nucleic acid chemistry, has a significantly improved preclinical profile
- Preclinical Efficacy and Pharmacokinetics of ALG-010133, an S-Antigen Transport-inhibiting Oligonucleotide Polymers (STOPS™) for the Treatment of Chronic Hepatitis B (CHB)
- Safety, Tolerability and Pharmacokinetics of Single Ascending Doses of ALG-000184, a Class II Capsid Assembly Modulator for the Treatment of Chronic Hepatitis B (CHB), in Healthy Volunteers (HV)
- Excellent preclinical characteristics of ALG-000184, a prodrug of the HBV capsid assembly modulator ALG-001075
AASLD 2020
- ALG-010133, S-Antigen Transport-inhibiting Oligonucleotide Polymer (STOPS) effectively inhibits HBsAg secretion in multiple Hepatitis B Virus (HBV) cell models
- ALG-055009, a potent, selective THR-B agonist for treatment of NASH, demonstrates significant cholesterol reduction in a Diet-Induced Obese (DIO) mouse efficacy model
- Best-in-class preclinical characteristics of ALG-000184, a prodrug of the capsid assembly modulator ALG-001075 for the treatment of chronic hepatitis B
- Characterization of thyroid hormone receptor agonists for the treatment of NASH by quantification of gene transcription in human hepatocytes
- Development of a best-in-class HBV ASO, ALG-020572, for the treatment of chronic hepatitis B
- S-Antigen Transport-inhibiting Oligonucleotide Polymer (STOPS™) ALG-010133 demonstrates a favorable preclinical profile for the treatment of chronic hepatitis B
- Tumor regression in a mouse model of hepatocellular carcinoma upon treatment with the STING agonist ALG-031048
EASL 2020
- ALG-000184, a prodrug of capsid assembly modulator ALG-001075, demonstrates best-in-class preclinical characteristics for the treatment of chronic hepatitis B
- Best in class hepatitis B virus anti sense oligonucleotides Next generation bridged nucleic acid chemistries significantly improve the therapeutic index by reducing hepatotoxicity
- Molecular, cellular and pharmacological characterization of beta selective partial agonists of human thyroid hormone receptor for the treatment of nonalcoholic steatohepatitis
- Combination drug interactions of hepatitis (HBV) S-antigen Transport-inhibiting oligonucleotide polymers in vitro
- Structural requirements for S-antigen Transport-inhibiting oligonucleotide polymer inhibition of hepatitis B surface antigen secretion